Birth and evolution of a new morphologic entity: collapsing glomerulopathy
==========================================================================

In the mid-1980s, the first descriptions of a very aggressive proteinuric disease with a glomerular pattern of collapse were published. Weiss *et al.* wrote the first clinicopathologic findings of what we now view as collapsing glomerulopathy (CGP) \[[@sfx029-B1]\]. They described six African-American patients who developed rapidly progressive renal failure, nephrotic syndrome, glomerular tuft collapse, podocyte hyperplasia and significant tubulointerstitial damage (Figure [1](#sfx029-F1){ref-type="fig"}A--C). Differently from the previously reported human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) phenotype \[[@sfx029-B2], [@sfx029-B3]\], these patients had negative serology for the HIV. Using a computerized medical record system, they convincingly argued that these patients represented a new disease entity \[[@sfx029-B2], [@sfx029-B3]\]. The association between HIV and CGP largely came about following a report by Cohen and Nast*.* describing nine HIV-positive patients with proteinuria and rapidly progressive renal disease \[[@sfx029-B4]\]. Morphologically, these patients consistently showed unique segmental tuft collapse with overlying podocyte hypertrophy and hyperplasia. In addition, microcystic tubular dilatation with inspissated, proteinaceous material and extensive protein resorption droplets within proximal tubular epithelium were described. While this entity shared many similarities with the entity Weiss *et al.* reported, it was termed HIV-associated nephropathy (HIVAN) due to the strong correlation with HIV/AIDS infection. In 1994, Detwiler *et al.* reported 16 predominantly African-American patients, with rapidly progressive renal failure, proteinuria and segmental to global glomerular tuft collapse \[[@sfx029-B5]\]. These findings shared extensive morphologic overlap with the patients described by Weiss *et al.*, and Cohen *et al.* and the findings were corroborated by a comprehensive study of 30 cases reported by D'Agati *et al.* in 1989 \[[@sfx029-B6]\]. In the mid-1990s, the original observations were confirmed by several authors. In 1994, Detwiler *et al.* reported 16 predominantly African-American, HIV-negative, patients with features similar to those described by Weiss *etal.* \[[@sfx029-B1]\], including rapidly progressive renal failure, proteinuria and segmental to global glomerular tuft collapse \[[@sfx029-B5]\]. Subsequently, others corroborated these results and with a larger study by Valeri *etal.*, the term collapsing focal segmental glomerulosclerosis was introduced in the literature \[[@sfx029-B7], [@sfx029-B8]\].

![CGP, morphologic indicators of *APOL1*-related nephropathy, underlying etiologies and mimics. (**A--D**) HIV--CGP. Biopsy from a 31-year-old African-American (AA) woman, HIV-positive, who presented with nausea and vomiting, hematuria and proteinuria, acute and chronic renal failure, creatinine 3.4 mg/dL. Serum albumin 2.1 g/L. (**A**) Global capillary loop wrinkling (collapse) and massive podocyte proliferation. Podocytes are filled with lipid droplets (silver stain ×200). (**B**) Markedly dilated tubules filled with eosinophilic material (H + E ×100). (**C**) Tubular reticular inclusions in endothelial cell \[electron microscopy (EM) ×20 000\]. (**D**) Multinucleated podocytes (thick arrow) lining collapsed capillary loops (thin arrow). Also present are cytoplasmic osmiophilic inclusions (lysosomes). (**E, F**)*APOL1* nephropathy. Renal biopsy is from a 51-year-old AA man who presented with hypertension, nephrotic-range proteinuria and chronic kidney disease. He was subsequently found to have two APOL1 risk alleles. (**E**) Biopsy shows segmental glomerular loop collapse and podocyte proliferation over the collapsed loops (silver ×200). Numerous solidified glomeruli were present (not shown). (**F**) Tubular atrophy thyroidization type and severe arteriosclerosis (PAS ×100). (**G--I**) Lupus membranous with CGP. Patient is a 27-year-old woman with nephrotic syndrome recently diagnosed with lupus. (**G**) CGP is shown. There are no spikes (silver stain ×200). (**H**) Immunofluorescence showed diffuse granular capillary loop deposits \[(immunoglobulin G IgG) ×200\]. (**I**) EM shows subepithelial and early intramembranous deposits. (**J--M**) Lupus with *APOL1*. The patient was an AA woman with well documented lupus serology seen for follow-up because of persistent proteinuria in spite of aggressive therapy. *APOL1* genotyping revealed two risk alleles (Figure [2](#sfx029-F2){ref-type="fig"}). (**J**) Segmental pilling up of visceral podocytes mimicking epithelial crescent (silver ×200). (**K**) Immunofluorescence showed diffuse full house immune deposits \[immunofluorescence (IF) ×50\]. (**L**) Crescent-like proliferation and marked tubular dilatation (silver ×100). (**M**) EM shows subendothelial and mesangial deposits. (**N, O)** Interferon-induced CGP. A 54-year-old man with multiple sclerosis treated with interferon beta1 alpha. Presented with proteinuria more than 5 g/24 h and preserved renal function. (**N**) Segmental capillary loop collapse and podocyte proliferation (silver ×200). (**O**) No tubulointerstitial damage (trichrome ×100). (**P--R**) Ischemic CGP in allograft kidney. The patient is a 43-year-old AA with deceased donor kidney 5 years prior to this biopsy. He presented with severe hypertension (HTN) and creatinine 4.5 mg/dL and increasing proteinuria. (**P**) Retracted glomerulus shows podocyte proliferation (silver ×200). (**Q**) Arteriolar thrombosis is identified adjacent to the glomerulus in (**P**) (silver stain ×200). (**R**) Diffuse C4d positivity in peritubular capillaries consistent with antibody mediated rejection (IF ×100). (**S**) Epithelial crescents mimic CGP. Shown is a glomerulus with podocyte proliferation (arrow points to mitotic podocyte) with no necrosis or fibrin deposits and vague capillary loop collapse. Patient was a 62-year-old man with rapidly progressing glomerulonephritis and pending serologies at the time of biopsy. No known predisposing factors for CGP. (**T**) Diabetes with CGP. The patient was a known diabetic for 10 years with acute onset nephrotic-range proteinuria. Biopsy shows podocyte proliferation over glomerular diabetic nodules (silver stain ×200).](sfx029f1){#sfx029-F1}

Later, studies by Barisoni *et al.* suggested a common pathologic mechanism between CGP and HIVAN that leads to a dysregulated podocyte phenotype in both HIVAN and CGP \[[@sfx029-B9]\]. This concept of common mechanisms of injury was based on three lines of evidence. First, both entities showed complete loss of normal podocyte phenotype utilizing known markers of podocytes (CALLA, GLEPP1, Podocalyxin, Synaptopodin, WT1, P27 and p57 were decreased while Cyclin D1, Cyclin E, Cyclin A, Ki-67, Desmin, Cytokeratin and CD68 were increased). Second, comparable numbers of podocytes were noted to enter the cell cycle in both diseases, in contrast to normal podocytes that are physiologically arrested, post-mitotic cells. Lastly, both diseases showed identical ultrastructural cytoarchitecture. Barisoni *et al.* subsequently proposed the term podocytopathy for diseases of the podocyte and developed a classification structure \[normal glomerular histology---minimal change disease (MCD); segmental glomerulosclerosis (FSGS); mesangial sclerosis---diffuse mesangial sclerosis (DMS); and capillary loop collapse---CGP\] \[[@sfx029-B10]\].

More recently, a concept has been proposed that is termed podocyte mitotic catastrophe (MC) that attempts to explain the etiology of podocytopathies such as collapsing lesions \[[@sfx029-B11]\]. To explain this concept, we can look to collapsing lesions in HIVAN. There is evidence that HIV can infect podocytes (and parietal epithelial cells), leading to podocyte mitosis and a switch to a proliferative podocyte phenotype where proliferating podocytes attempt to divide unsuccessfully. The morphologic result of this switch in phenotype is podocyte multi-nucleation (Figure [1](#sfx029-F1){ref-type="fig"}D), previously thought of as a compensatory mechanism of podocyte repair. However, this phenotype switch and podocyte multi-nucleation has now been suggested to be a distinct podocyte death mechanism---MC \[[@sfx029-B11], [@sfx029-B12]\]. MC is believed to be a conflict in the podocyte cell cycle that prevents podocytes from dividing and leads to their detachment from the glomerular basement membrane (GBM). This is a separate mechanism from crescent formation where ruptured capillary loops allow blood leakage into Bowman's space, which promotes epithelial cell proliferation (both visceral and parietal) \[[@sfx029-B13]\]. The connection of podocyte proliferation and aberrant cell death through attempted mitosis (MC) is still a new concept that may potentially help explain the pathogenesis of CGP. However, to date, little has been studied experimentally or clinically on this topic despite its intriguing implications.

Throughout the discovery phase of CGP, several secondary etiologies/associations were reported such as renal vascular ischemia, infection other than HIV (hepatitis C, HTLV-1, parvovirus B19 and loa loa filariasis), systemic lupus erythematosus, drugs \[such as pamidronate, interferon (Figure [1](#sfx029-F1){ref-type="fig"}N and O), anabolic steroids and heroin\], hematologic neoplasia and familial types \[[@sfx029-B14]\]. Throughout the 2000s, CGP saw mostly growth in its associations without significant change in its morphologic descriptions.

CGP in the era of genetics
==========================

The discovery of the apolipoprotein L1 (*APOL1*) G1 and G2 risk variants (located on the long arm of chromosome 22 at position 13.1) would prove to be tremendously important in shaping our understanding of CGP \[[@sfx029-B23]\]. These commonly occurring variants in the *APOL1* gene are responsible for the increased burden of non-diabetic renal disease affecting African-Americans \[[@sfx029-B24]\]. Patients with any combination of two of these risk alleles inherit a markedly increased risk of renal disease and progression to end-stage renal disease.

The G1 variant is a pair of two non-synonymous single nucleotide polymorphisms (SNPs) in almost complete linkage disequilibrium. The G2 variant is an in-frame deletion of the two amino acid residues, N388 and Y389 \[[@sfx029-B25]\]. The gene product, *APOL1* protein, is a minor component of high-density lipoprotein that is found in vascular endothelium, liver, heart, lung, placenta, podocytes, proximal tubules and arterial cells \[[@sfx029-B26]\]. The protein also has a secreted form that circulates in the blood and is known for its roles in trypanosomal lysis, autophagic cell death, lipid metabolism and other biological activities \[[@sfx029-B27]\]. The *APOL1* risk variants are common in the African-American population due to selection pressure related to the protection they confer from *Trypanosoma brucei rhodesiense* infection \[[@sfx029-B27]\].

The role of *APOL1* in kidney health is still not entirely understood but there is at least one report of an *APOL1* null Indian man who had no evidence of kidney disease while infected with trypanosomes \[[@sfx029-B28]\]. This suggests that *APOL1* may be dispensable for normal kidney function and that *APOL1* risk variants may acquire toxic functions that damage the kidney. CGP has been shown to be associated with the presence of homozygosity for *APOL1* risk alleles in a number of disease settings including HIV, lupus nephritis, membranous glomerulopathy and in association with interferon and pamidronate treatment \[[@sfx029-B17], [@sfx029-B19], [@sfx029-B29]\]. It appears that both glomerular injury and inflammatory 'second hits' may potentiate kidney damage in patients with *APOL1* risk variants \[[@sfx029-B25], [@sfx029-B32]\]. In addition, while identification of *APOL1* risk variants requires genetic testing, Larsen *et al.* have recently described key morphologic features \[microcystic tubular dilatation, thyroid-type tubular atrophy (Figure [1](#sfx029-F1){ref-type="fig"}E and F) and a predominance of solidified/disappearing-type global glomerulosclerosis\] that, when found in combination, have significant association with underlying *APOL1* gene risk variant homozygosity \[[@sfx029-B33]\].

CGP in children
===============

While uncommon, CGP has been reported in children, especially in the setting of underlying *APOL1* risk variants \[[@sfx029-B34]\]. Kopp *et al.* described a pediatric subset of their cohort with two underlying *APOL1* risk variants \[[@sfx029-B34]\]. While the pediatric patients showed less FSGS than their older cohorts, CGP was identified within this population, usually after 12 years of age \[[@sfx029-B34]\]. Subsequent studies of *APOL1* in children have shown a more aggressive course of renal disease in those with homozygosity for *APOL1* risk alleles \[[@sfx029-B35]\].

In addition to the *APOL1* association, other genetic diseases may be associated with CGP in children, especially ones with underlying mitochondrial dysfunction (action myoclonus---renal failure syndrome, ZMPSTE24 mandibuloacral dysplasia/action myoclonus, mitochondrial cytopathy coenzyme Q10 (CoQ10), CoQ2 deficiency and sickle cell anemia) \[[@sfx029-B36]\]. Whether mitochondria in general may represent a common pathogenic pathway for CGP is intriguing because mitochondrial damage induces cell death and cytochrome C release, which have also been shown to play a role in CGP development \[[@sfx029-B36], [@sfx029-B37]\].

Another point to be considered in childhood CGP is the potential morphologic resemblance of CGP and DMS. While these entities are often straightforward to distinguish, both CGP and DMS may show podocyte proliferation and differentiation may be difficult in rare cases of DMS where mesangial sclerosis is not present. However, this is a very rare occurrence as DMS frequently shows additional glomerular findings (e.g. fetal glomeruli) and clinical manifestations (e.g. Denys--Drash syndrome) that may help in differentiation \[[@sfx029-B38]\]. As DMS may be caused by treatable entities (CoQ2, CoQ10 and other mitochondrial enzyme deficiency), differentiation is imperative \[[@sfx029-B36], [@sfx029-B37]\].

CGP in the allograft kidney
===========================

CGP in the renal allograft has a similar set of potential etiologies to CGP in the native kidney \[[@sfx029-B39]\]. However, two potential scenarios deserve special attention. First, *APOL1* risk variants are still an important etiology of CGP in the renal allograft; however, it is the *APOL1* status of the allograft donor that is associated with disease \[[@sfx029-B40]\]. And, should CGP that is associated with donor *APOL1* risk variants be identified, correlation with the other transplanted kidney (if both of the donor's kidneys were transplanted) should be attempted as both will be affected \[[@sfx029-B40]\]. The occurrence of *APOL1-*associated kidney disease in renal transplants has raised the important question of *APOL1* gene testing of allografts from high-risk populations. However, this topic is controversial and would currently be difficult to implement due to utility and turnaround-time limitations associated with genetic testing \[[@sfx029-B41]\].

Next, is the issue of how to interpret focal collapsing lesions in the renal allograft in the setting of ischemia and microangiopathy (Figure [1](#sfx029-F1){ref-type="fig"}P--R). Although primarily reported in native kidneys, collapsing lesions can be seen in thrombotic microangiopathy (TMA) and other ischemic conditions in the allograft, and often occur in glomeruli with significant microangiopathic injury (Figure [1](#sfx029-F1){ref-type="fig"}Q) \[[@sfx029-B42]\]. In this setting, there should be a high threshold for the diagnosis of CGP. Features we find helpful to suggest a diagnosis of CGP include involvement of glomeruli that are seemingly uninvolved by microangiopathy and background tubulointerstitial changes typically seen in CGP (Figure [1](#sfx029-F1){ref-type="fig"}G and H). Clinical symptoms supportive of CGP (nephrotic-range proteinuria and acute renal failure) are not uncommon in TMA and may not be helpful. Descriptive diagnoses or comments explaining the morphology in this setting are potentially useful and alerts the nephrologist to monitor the patient during and after treatment of the TMA to see if they have additional clinical features to corroborate the presence of a concurrent CGP (such as an abnormal clinical course, *APOL1* risk alleles or a known secondary disease such as HIV).

CGP: causes and distribution from a large database
==================================================

In our renal biopsy, database over a 15.5-year period, 1201 cases of CGP were identified representing 1.4% of renal biopsies performed over that time period (∼70 000). Over our study interval (the last 6 months of 2015) a total of 88 sequential CGP cases were retrieved as a focused subset. These cases represent 1.3% of the total renal biopsies over this period, a frequency similar to that of the entire database. Our biopsy database was queried for cases containing the term 'CGP' within the diagnosis or comment (July--December 2015). Inclusion criteria for this study consisted of: native and adequate renal biopsy tissue for diagnosis, unequivocal diagnosis of CGP and absence of proliferative lupus nephritis with crescents. A total of 88 cases met inclusion criteria and were included in the cohort.

Average patient age was 44 (11--83 range) years old with a nearly equal male:female ratio (48% male, 52% female). As in previous studies, a marked predilection for African ancestry was noted, with 84% of patients being African-American (see Table [1](#sfx029-T1){ref-type="table"}). The reasons for renal biopsy varied, with the most common presentation being nephrotic-range proteinuria and acute renal failure (51% of patients). Chronic kidney disease was noted in a fraction (17%) of patients. Markedly elevated serum creatinine values were common, with an average of 4.15 mg/dL (0.8--17.8 mg/dL range), and proteinuria was most often of the nephrotic range (72% of patients) with an average of 11.2 g/day (0.8--31 g/day range). Hematuria was noted in 28% of patients (however, this data point may not be reliable as \<50% of patients had this data available for review). Hypertension was frequently present (92% of patients) at the time of biopsy. Table 1.Clinical findings and etiologiesAverage age44 years (11--83 range)Male:female ratio1:1Ethnicity (%) African-American84 Caucasian13 Hispanic1Average serum creatinine (mg/dL)4.15 (0.8--17.8 range)Average proteinuria (g/day)11.2 (0.8--31 range) Nephrotic syndrome (%)86Hypertension (%)92Etiology of collapsing glomerulopathy (%) Idiopathic disease (*APOL1* not tested)77 HIV/AIDS (HIVAN)17 Chronic ischemic vascular disease3* APOL1*-associated nephropathy2 Heroin nephropathy\<1 Hepatitis C\<1

While a potential etiology of CGP was identified in a small subset of patients, 77% of patients (68 patients) had idiopathic disease (see Table [2](#sfx029-T2){ref-type="table"}); however, none of these patients was tested for *APOL1* risk variants. The most common etiology identified in these patients was HIV/AIDS (17%; 15 patients) and among these 15 patients with HIV/AIDS, 10 were African-American, one was Caucasian and four had unknown ancestry. Three non-African ancestry patients (3%) showed ischemic glomerular and tubulointerstitial changes in addition to arteriosclerosis, and a history of hypertension and an ischemic etiology was favored. A single patient (1%) had a history of recent heroin use and likely represented heroin nephropathy while another single patient (1%) had a history of active hepatitis C infection in the absence of other known etiologies of CGP. Additionally, eight patients had a history of systemic lupus erythematosus, with four showing membranous lupus nephritis (ISN/RPS Class V) (Figure [1](#sfx029-F1){ref-type="fig"}G--I). *APOL1* genetic testing was only requested and performed in two patients, both with systemic lupus, and both (2%) showed homozygosity for *APOL1* risk alleles (Figure [1](#sfx029-F1){ref-type="fig"}J--M and Figure [2](#sfx029-F2){ref-type="fig"}). This overall distribution of etiologies is comparable to other, similar case series in CGP \[[@sfx029-B5], [@sfx029-B7], [@sfx029-B8], [@sfx029-B45], [@sfx029-B46]\]. Table 2.CGP associations from published studies and our dataInfectious micro-organisms HIV, parvovirus 19, cytomegalovirus, hepatitis C Tuberculosis, *Campylobacter* enteritisAutoimmune diseases Lupus, lupus-like disease, connective tissue disease, Still's diseaseHereditary* APOL1*-related nephropathy Mitochondrial cytopathies CoQ2 and CoQ10 deficiency, action myoclonousDrugs Interferon Bisphosphonates Anabolic steroids Heroin Valproic acid

![*APOL1* genotyping. Taqman SNP genotyping data performed on a real-time PCR system with primers designed to detect the *APOL1* risk alleles G1 (rs73885319) and G2 (rs71785313). The genotypes cluster according to whether they are homozygous for the risk allele being tested (dark blue), homozygous wild type (red) or heterozygous for the risk allele (green). The black boxes represent no-template controls. This patient (light blue) is heterozygous for each risk allele, indicating that she is compound heterozygous for G1 (**A**) and G2 (**B**) *APOL1* risk alleles and, therefore, at risk for *APOL1*-associated nephropathy.](sfx029f2){#sfx029-F2}

A second biopsy diagnosis was present in 52% (46/88) of patients. The most common secondary diagnosis by a wide margin was acute tubular injury followed by glomerular immune complex deposition, acute/chronic tubulointerstitial nephritis, diabetic glomerulopathy and non-proliferative lupus nephritis.

The difficult diagnosis; entities mimicking CGP
===============================================

In most CGP cases, morphologic diagnosis is straightforward when histopathologic criteria are applied. However, cases do arise that are more nuanced and raise considerable disagreement even among experienced renal pathologists as to whether a diagnosis of CGP should be invoked. These cases often show some features of CGP (Figure [1](#sfx029-F1){ref-type="fig"}S) but lack convincing glomerular morphologic changes or the characteristic accompanying tubulointerstitial changes are not present. Also, glomerular epithelial hyperplasia can become particularly florid, appearing as crescentic glomerulonephritis. This particular difficulty is often encountered on a background of membranous glomerulopathy, diabetic glomerulopathy, or membranous lupus nephritis or TMA, further complicating interpretation \[[@sfx029-B30], [@sfx029-B31], [@sfx029-B47]\]. As no data exist detailing any specific test to differentiate crescents from CGP this formidable question is often relegated to experience and opinion. In the case of underlying diabetic glomerulopathy, Salvatore *et al.* have recently addressed the question of collapsing lesions superimposed on diabetic glomerulopathy (Figure [1](#sfx029-F1){ref-type="fig"}T) and their study suggested that these lesions might be attributable to ischemia \[[@sfx029-B47]\]. Similarly, CGP in TMA is thought to be due to ischemia. The recent study by Buob *etal.* addressed the association from the endothelial injury point of view, bringing this mechanism into the pathogenesis of CGP \[[@sfx029-B42]\].

Overall, we find the presence of fibrinoid necrosis, karyorrhexis, glomerular basement membrane rupture and red blood cell casts to be helpful indicators of crescent formation while the absence of these findings with the presence of protein resorption droplets admixed with the hypertrophied and hyperplastic podocytes, significant tubular intracytoplasmic protein resorption drops, microcystic tubular dilatation, thyroid type tubular atrophy and a predominance of solidified or disappearing-type global glomerulosclerosis suggests CGP.

Conclusions
===========

CGP is a morphologic lesion representing a common endpoint from multiple etiologies. It is a podocytopathy that is often secondary to *APOL1* risk variants but has also been associated with infection, drugs, ischemia, hematologic neoplasia and autoimmune disease. Morphological features of CGP are time-tested and well-recognized today. However, there are several confounding morphologies that may provide diagnostic difficulty. The discovery of *APOL1* risk variants changed the way we understand and classify CGP and provide, in part, a unifying etiology for some of the underlying associations, leading to a more pathogenesis-based approach to this multifaceted diagnosis.
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